{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "In preclinical mouse tumor models, an intratumoral mRNA vaccine combined with anti-PD-L1 is reported to improve tumor control compared with control conditions.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        },
        {
          "quote": "5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, so efficacy in mice does not guarantee clinical benefit." 
    },
    {
      "claim_id": "C02",
      "claim": "In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status is associated with better survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        }
      ],
      "caveat": "Because the human analysis is retrospective and non-randomized and vaccination timing varied, the association cannot be interpreted as a definitive causal effect." 
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccination is reported to broaden tumor antigen presentation, increasing the fraction of tumor proteins observed in immunopeptidomics and in the MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings." 
    },
    {
      "claim_id": "C04",
      "claim": "The authors propose that intratumoral mRNA vaccination triggers type I interferon signaling in tumors, contributing to improved immune priming for checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        }
      ],
      "caveat": "The report summarizes a proposed mechanistic chain; without full experimental detail here, the magnitude and generality of interferon induction across models could vary." 
    },
    {
      "claim_id": "C05",
      "claim": "Type I interferon signaling appears necessary for the sensitization effect, because IFNAR1 blockade is reported to eliminate the benefit.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "This necessity claim is based on a specific perturbation (anti-IFNAR1) described in summary form, and may depend on tumor model context and experimental conditions." 
    }
  ]
}
